Sangani Hospitals Limited is a rapidly expanding multi-speciality healthcare provider headquartered in **Gujarat, India**. The company operates a strategic **hub-and-spoke model** designed to deliver a continuum of care—ranging from primary diagnostics to complex tertiary surgeries—to the underserved regional markets of **Keshod**, **Veraval**, and **Junagadh**. Following its successful listing on the **NSE Emerge Platform** in **August 2023**, the company has transitioned from a family-led regional practice into a corporatized healthcare network. With a current capacity of **170 beds** as of late 2025, Sangani Hospitals is leveraging public capital to fund inorganic growth, vertical integration into pharmaceutical distribution, and the management of third-party healthcare assets. --- ### **Clinical Infrastructure & Regional Footprint** The company’s operational core consists of three primary facilities, each positioned to capture specific patient demographics and acuity levels. | Facility Name | Location | Strategic Role & Certifications | | :--- | :--- | :--- | | **Sangani Hospital** | Keshod, Junagadh | Multi-speciality hub; Primary, Secondary, and Tertiary care; strategically located near transport hubs for rural accessibility. | | **Sangani Super Speciality Hospital** | Veraval, Gujarat | High-acuity Tertiary care center; **NABH Certified**; focus on advanced surgical and diagnostic disciplines. | | **Health Plus Hospital** | Junagadh, Gujarat | Operational since **June 17, 2024**; established via a revenue-sharing management model to penetrate the Junagadh urban market. | **Quality Benchmarks:** * **ISO 9001:2015** certification across the group for Quality Management Systems. * **NABH Accreditation** for the Veraval unit, covering general medicine, surgery, and specialized diagnostics. --- ### **Specialized Medical Portfolios & Service Delivery** Sangani Hospitals operates under a single reportable segment: **Healthcare Related Services**. The clinical focus is diversified across high-margin surgical specialties and high-volume chronic care. * **Tertiary Care Specialties:** Cardiac sciences (**ICCU, ECHO-TMT, EECP**), Neurosciences, Orthopaedics (including **Joint Replacement** and a dedicated **Trauma Unit**), and Renal sciences. * **Maternal & Child Health:** Comprehensive services including **OBST & Gynee**, **USG-Doppler**, and neonatal care. * **Internal Medicine & Diagnostics:** Specialized units for **Endoscopy**, **PFT (Pulmonary Function Test)**, and a **Diabetic Clinic**. * **ENT & Specialized Surgery:** Advanced **Head & Neck Surgery**, **Laser Surgery**, **Audiology**, and a specialized **Vertigo Clinic**. * **Public Health Integration:** A major participant in the **Ayushman Bharat (PMJAY)** and **Mukhyamantri Amrutum (MA) Yojana** schemes. The company performs over **6,000 annual dialysis sessions** for more than **600 patients** under these government initiatives. --- ### **Strategic Growth: The Pivot to Inorganic Expansion** In a significant strategic shift during the **2025-26** period, the company redirected its capital allocation strategy. Originally intended for organic expansion of existing sites, shareholders approved the reallocation of **₹8.09 crore** (**62.71%** of total **IPO** proceeds) toward strategic acquisitions. **Key Investment: Sadbhavna Hospital** The company invested **₹11.29 crore** to acquire a **55% controlling stake** in **Sadbhavna Hospital and Medical Research Centre Private Limited**. * **Rationale:** This acquisition provides an immediate boost to the consolidated topline and establishes a presence in a major urban hub, serving as a base for further regional expansion. **Asset-Light Management Model:** The company is aggressively pursuing growth through **Memorandums of Understanding (MoUs)** and revenue-sharing agreements, allowing for expansion without heavy capital expenditure: * **Dr. Bhanuben Nanavati Hospital (Chorvad):** Management and operations agreement. * **Devasya Hospital (Keshod):** Partnership for specialized **Surgical and Gynaecology** services. * **Ashirvad Hospital (Mangrol):** Executed MoU for potential future acquisition. --- ### **Vertical Integration & Subsidiary Operations** To capture a larger share of the healthcare value chain, Sangani Hospitals has integrated pharmaceutical and diagnostic supply chains into its corporate structure. * **Pharmaceutical Distribution:** Holds **95% ownership** in **M/s. Ankur Distributors** (acquired April 2022), which manages the group's internal and external pharma supply chain. * **MOA Amendment:** In **September 2025**, the company altered its Memorandum of Association to permit wholesale, retail, and distribution of pharmaceutical, biological, and nutraceutical products. * **Ancillary Revenue:** Operation of in-house **pathology laboratories** and **medical stores** ensures captured revenue from inpatient and outpatient prescriptions. --- ### **Financial Performance & Capital Structure** The company has maintained a trajectory of top-line growth, though recent investments in expansion have impacted short-term margins. **Financial Highlights (Consolidated):** | Metric (₹ in Crores) | FY 2024-25 | FY 2023-24 | FY 2022-23 | | :--- | :--- | :--- | :--- | | **Total Revenue** | **22.79** | **16.52** | **15.76** | | **Net Profit** | **2.59** | **2.70** | **1.48** | | **Revenue Growth (YoY)** | **37.9%** | **4.8%** | **-** | **Capital History:** * **IPO Details:** Listed on **August 17, 2023**, raising **₹15.17 crore** by issuing **37,92,000 shares** at **₹40 per share**. * **Share Capital:** Authorised capital was doubled from **₹10 crore** to **₹20 crore** to facilitate growth. Paid-up capital stands at approximately **₹13.78 crore**. * **Dividend Policy:** The Board has opted to **retain earnings** to fund ongoing expansion and has not recommended dividends for the recent fiscal periods. --- ### **Risk Matrix & Operational Outlook** The company’s future valuation is tied to its ability to integrate new acquisitions and maintain high utilization rates across its expanded bed capacity. | Risk Category | Critical Factors | | :--- | :--- | | **Operational Efficiency** | Sensitivity to **Occupancy Rates**, **Average Length of Stay (ALOS)**, and **Revenue Per Occupied Bed (ARPOB)**. | | **Integration Risk** | The **55% stake acquisition** in Sadbhavna Hospital requires successful cultural and operational integration to realize expected **ROI**. | | **Human Capital** | High dependency on **Key Medical Professionals**; attrition in specialized departments (Urology, Orthopaedics) could impact patient retention. | | **Regulatory Environment** | Exposure to changes in **PMJAY/MA Yojana** reimbursement rates and healthcare pricing regulations. | | **Financial Liquidity** | Post-acquisition requirements for **Infrastructure Upgrades** and **Technology** may strain short-term **Cash Flows**. | **Internal Controls:** The company maintains a robust internal control system to ensure **Reliable Financial Reporting** and compliance with statutory requirements. As of **March 2024**, the group reported **zero pending litigations** that would materially impact its financial standing.